Grace Therapeutics (GRCE) Earnings Analysis
Grace Therapeutics (GRCE) has no confirmed upcoming earnings date. Last quarter (2026-06-18) it beat with EPS -0.07 USD vs -0.24 USD est (+70.8%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -4.26.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GRCE next report earnings?
No confirmed upcoming earnings date is currently scheduled for GRCE. This page updates as the calendar is published.
GRCE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-06-18 | -0.07 USD | -0.24 USD | +70.8% | Beat |
| 2026-02-12 | -0.14 USD | -0.09 USD | -55.6% | Miss |
| 2025-11-13 | -0.15 USD | -0.12 USD | -25% | Miss |
| 2025-06-23 | 0.0647 USD | -0.2 USD | +132.3% | Beat |
| 2025-02-13 | -0.26 USD | -0.24 USD | -8.3% | Miss |
| 2024-08-09 | -0.24 USD | -0.265 USD | +9.4% | Beat |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
GRCE valuation and analyst view
| Trailing P/E | -4.26 |
|---|---|
| Trailing EPS | -0.5466 USD |
| Price / book | 0.61 |
| Dividend yield | 0.00% |
| Market cap | 0.04B |
| Analyst consensus | Buy (2 buy / 0 hold / 0 sell) |
| Avg price target | 4 USD |
Related research pages
Frequently asked questions
When is Grace Therapeutics (GRCE)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for GRCE. This page updates as the calendar is published.
Did GRCE beat earnings last quarter?
In its 2026-06-18 report, GRCE posted EPS of -0.07 USD versus a -0.24 USD estimate — a beat of 70.8%.
What is GRCE's earnings track record?
Over the last 6 reported quarters with consensus data, GRCE beat estimates 3 times (50%).
What is GRCE's current P/E ratio and EPS?
GRCE trades at a trailing P/E of -4.26 on trailing EPS of -0.5466014868479898 USD.
What do analysts rate GRCE?
Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 4 USD.